Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 330 participants.
Also called NCT07220759
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 330 participants
- Sponsor
- Registry
-
NCT07220759
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Canada, Croatia, Czechia, Hungary, Romania, Slovakia, South Korea, Switzerland, United Kingdom
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT07220759. Randomized; quadruple masking; primary purpose treatment. Start 2025-11-05 (actual); primary completion 2027-05-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
- Acronym
- RENEW 2
- Condition
- Overweight
- Condition
- Obesity
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Cagrilintide
- Intervention (Drug)
- Placebo (matched to Cagrilintide)
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct07220759- Content hash
52d5ab968f0de845a676a6badd22f5efdd52af57aeffd25a7e23ae718971f731